These are in addition to two targets Abbott selected for advancement in April 2005. Abbott now has a total of four targets under investigation from the strategic collaboration established between the companies to discover, develop and commercialize therapies for the treatment of cancer.
The collaboration encompasses the development of therapeutic antibodies and small molecule drugs against over-expressed cell-surface proteins that have been associated with cancer and identified as therapeutic targets through proteomics research at Celera Genomics. Any of these antigens may be selected for therapeutic development at Abbott.
“This is further validation of the value our proteomics platform has yielded in discovering and validating targets in pancreatic, lung, colon, breast, gastric, prostate and renal cancers,” said Kathy Ordonez, president of Celera Genomics.